Free tool
FAERS Monitor: Fylnetra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761084 or its brand name (Fylnetra, Pegfilgrastim-Pbbk). Reports on generic versions are filed under their own applications.
Reports
11,979
Serious
11,039
92% of reports
Hospitalization
6,045
Death reported
1,860
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- febrile neutropenia2,020
- neutropenia1,176
- pyrexia912
- nausea854
- fatigue828
- off label use782
- diarrhoea769
- anaemia748
- thrombocytopenia612
- pneumonia535
- vomiting529
- death502
- dyspnoea476
- neuropathy peripheral436
- decreased appetite363
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 25 |
| 2005 | 35 |
| 2006 | 10 |
| 2007 | 38 |
| 2008 | 54 |
| 2009 | 105 |
| 2010 | 111 |
| 2011 | 282 |
| 2012 | 423 |
| 2013 | 486 |
| 2014 | 349 |
| 2015 | 509 |
| 2016 | 370 |
| 2017 | 450 |
| 2018 | 815 |
| 2019 | 656 |
| 2020 | 841 |
| 2021 | 968 |
| 2022 | 1,069 |
| 2023 | 1,159 |
| 2024 | 1,335 |
| 2025 | 1,112 |
| 2026 | 777 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,180 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 2,020 | 55.1 | 52.9 | 104,339 |
| neutropeniaSignal | 1,176 | 15.3 | 14.5 | 15,681 |
| thrombocytopeniaSignal | 612 | 9.7 | 8.9 | 4,740 |
| neuropathy peripheralSignal | 436 | 8.1 | 7.4 | 2,698 |
| anaemiaSignal | 748 | 6.9 | 6.4 | 3,794 |
| pyrexiaSignal | 912 | 4.6 | 4.4 | 2,635 |
| pneumoniaSignal | 535 | 2.9 | 2.7 | 676 |
| decreased appetiteSignal | 363 | 2.7 | 2.5 | 405 |
| diarrhoeaSignal | 769 | 2.1 | 2.0 | 451 |
| vomiting | 529 | 2.0 | 1.8 | 260 |
| nausea | 854 | 1.9 | 1.8 | 374 |
| fatigue | 828 | 1.9 | 1.7 | 346 |
| off label use | 782 | 1.6 | 1.5 | 167 |
| dyspnoea | 476 | 1.5 | 1.4 | 75 |
| death | 502 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.